Tutkimus CA-4948:sta potilailla, joilla on uusiutuneita tai refraktorisia hematologisia pahanlaatuisia kasvaimia
TakeAim-lymfooma: Avoin, annoksen nosto- ja annoksenlaajennuskoe, jossa arvioidaan suun kautta annetun CA-4948:n turvallisuutta, farmakokinetiikkaa, farmakodynamiikkaa ja kliinistä aktiivisuutta potilailla, joilla on uusiutuneita tai refraktorisia hematologisia pahanlaatuisia kasvaimia
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies.
This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete).
Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles.
Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Ahmed Hamdy, MD
- Puhelinnumero: 617-503-6500
- Sähköposti: clinicaltrials@curis.com
Opiskelupaikat
-
-
-
Barcelona, Espanja
- Rekrytointi
- University Hospital Vall d'Hebron
-
Madrid, Espanja
- Rekrytointi
- MD Anderson Cancer Center Madrid
-
Seville, Espanja
- Rekrytointi
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Beersheba, Israel
- Rekrytointi
- Hematology Department Soroka UMC / Heanatology Department
-
Haifa, Israel
- Rekrytointi
- Rambam Medical Center
-
Jerusalem, Israel
- Rekrytointi
- Hadassah Medical Center / Ein-Carem
-
-
-
-
-
Cuneo, Italia
- Rekrytointi
- Università di Torino Croce e Carle
-
Florence, Italia
- Rekrytointi
- SODc Ematologia Azienda Ospedaliera Universitaria Careggi
-
Meldola, Italia
- Rekrytointi
- IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milan, Italia
- Rekrytointi
- IRCCS San Raffaele Scientific Institute
-
-
-
-
-
Gdansk, Puola
- Rekrytointi
- Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
-
Krakow, Puola
- Peruutettu
- Oddzial Kliniczny Hematologii
-
Warsaw, Puola
- Rekrytointi
- NarodowyInstytutu Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytutu Badawczy
-
-
-
-
-
Bordeaux, Ranska
- Rekrytointi
- Institut Bergonie
-
Marseille, Ranska
- Rekrytointi
- Hopital de la Timone
-
Paris, Ranska
- Rekrytointi
- Hospital Pitie Salpetriere
-
Paris, Ranska
- Rekrytointi
- Institut Curie Hospital
-
-
-
-
-
Prague, Tšekki
- Rekrytointi
- Všeobecná fakultní nemocnice v Praze
-
-
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85013
- Rekrytointi
- St. Joseph's Hospital and Medical Center
-
Phoenix, Arizona, Yhdysvallat, 85054
- Valmis
- Mayo Clinic
-
-
California
-
Duarte, California, Yhdysvallat, 91010
- Rekrytointi
- City of Hope
-
Santa Monica, California, Yhdysvallat, 90404
- Rekrytointi
- Providence St. John's Health Center
-
Santa Monica, California, Yhdysvallat, 90404
- Peruutettu
- UCLA Department of Medicine - Hematology/Oncology
-
-
Connecticut
-
New Haven, Connecticut, Yhdysvallat, 06510
- Valmis
- Smilow Cancer Hospital at Yale-New Haven
-
-
Florida
-
Jacksonville, Florida, Yhdysvallat, 32224
- Rekrytointi
- Mayo Clinic
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Rekrytointi
- Northwestern Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02215
- Rekrytointi
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Yhdysvallat, 55905
- Rekrytointi
- Mayo Clinic
-
-
Nebraska
-
Omaha, Nebraska, Yhdysvallat, 68198
- Rekrytointi
- Fred and Pamela Buffett Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Yhdysvallat, 07601
- Valmis
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, Yhdysvallat, 14263
- Rekrytointi
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Yhdysvallat, 10065
- Rekrytointi
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Yhdysvallat, 10032
- Peruutettu
- Columbia University Irving Medical Center
-
New York, New York, Yhdysvallat, 10029
- Rekrytointi
- Mt Sinai
-
-
North Carolina
-
Durham, North Carolina, Yhdysvallat, 27710
- Rekrytointi
- Duke University Medical Center, Duke Cancer Center
-
-
Ohio
-
Cleveland, Ohio, Yhdysvallat, 44195
- Rekrytointi
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97225
- Rekrytointi
- Providence Neurological Specialties West
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Valmis
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15232
- Rekrytointi
- UPMC Hilman Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Yhdysvallat, 37920
- Valmis
- University of Tennessee Medical Center
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75235
- Aktiivinen, ei rekrytointi
- UT Southwestern Medical Center
-
Houston, Texas, Yhdysvallat, 77030
- Rekrytointi
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Yhdysvallat, 84112
- Rekrytointi
- Huntsman Cancer Institute, University of Utah
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98195
- Rekrytointi
- University of Washington Medical Center
-
Seattle, Washington, Yhdysvallat, 98104
- Valmis
- Swedish Cancer Institute
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Males and females greater than or equal to 18 years of age
-
Life expectancy of at least 3 months
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
-
Histopathologically confirmed diagnosis of PCNSL (medical record is acceptable). Cerebral biopsies are not required if imaging reveals typical images of PCNSL.
- Participants with parenchymal lesions must have unequivocal evidence of disease progression (e.g., presence of at least 1 measurable target lesion [≥ 10 millimeters (mm) and ≤ 40 mm in the longest diameter on brain magnetic resonance imaging [MRI] or head computed tomography [CT] on imaging within 28 days prior to Cycle 1 Day 1]). In cases where the tumor size is smaller but still measurable and located at a critical central nervous system (CNS) location, disabling the participant and/or causing symptoms, this participant may be eligible following a discussion with the Sponsor Medical Monitor.
- For participants limited to leptomeningeal involvement, cerebrospinal fluid (CSF) analysis (cytology and/or flow cytometry) with or without additional imaging (MRI) of the spine as clinically indicated is required to document abnormal cells within 28 days prior to Cycle 1 Day 1.
Exclusion Criteria for Part B and Part C
-
Participants with only intraocular PCNSL without brain lesion or CSF involvement, T-cell lymphoma, systemic presence of lymphoma, or non-CNS lymphoma metastatic to the CNS
-
Evidence of systemic lymphoma. This must be demonstrated by a positron emission tomography (PET) scan (or CT scan with contrast if applicable) of the chest, abdomen, and pelvis at Screening (testicular ultrasound may be considered to exclude a testicular lymphoma disseminated to the brain).
-
Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) or prior history of systemic lymphoma, unless the participant has been free of the disease for ≥ 3 years.
-
Active malignancy other than PCNSL requiring systemic therapy
-
Previous BTKi treatment (Part C only).
-
History of Grade ≥ 3 rhabdomyolysis without complete recovery
-
Requirement for urgent therapy due to uncontrolled tumor mass/edema effects.
-
Received external beam radiation therapy to the CNS within 28 days prior to Cycle 1 Day 1.
-
Received prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1; allogeneic hematopoietic stem cell transplant (HSCT) within 60 days prior to Cycle 1 Day 1; or had clinically significant graft-versus-host disease (GVHD) requiring ongoing up-titration of immunosuppressive medications prior to Screening (with the exception of a BTKi for Part B only).
Note: The use of a stable or tapering dose of immunosuppressive therapy post-HSCT and/or topical steroids for ongoing skin GVHD is permitted with Sponsor Medical Monitor approval
-
Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 14 days or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1 (with the exception of ibrutinib or other BTKi for Part B only, which may be continued until the day before Cycle 1 Day 1)
-
Prior history of hypersensitivity or anaphylaxis to emavusertib, ibrutinib or any of their excipients.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Emavusertib (CA-4948) dose escalation
Part A1: Dose-level cohorts with up to approximately 6 participants each will be used to define the Maximum Tolerated Dose (MTD) for emavusertib. |
Emavusertib will be provided as a tablet dosage form to be taken BID.
Muut nimet:
|
|
Kokeellinen: Emavusertib (CA-4948) and ibrutinib dose escalation
Part A2: Evaluate escalating dose levels of oral emavusertib in combination with 560 mg QD or 420 mg QD of oral ibrutinib. The starting dose of emavusertib to be used in combination will be 200 mg BID. It is anticipated that 12 to 20 participants at a potential dose level will be required to establish optimal combination dosing. |
Emavusertib will be provided as a tablet dosage form to be taken BID.
Muut nimet:
Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD. |
|
Kokeellinen: Emavusertib (CA-4948) and ibrutinib dose expansion
In two Expansion Cohorts (Part B), emavusertib in combination with ibrutinib will be administered in participants with R/R PCNSL who have progressed on a BTKi. In Cohort 1, emavusertib 100 mg BID will be administered with ibrutinib 560 mg QD consecutively in 28-day treatment cycles. In Cohort 2, emavusertib 200 mg BID will be administered with ibrutinib 560 mg QD consecutively in 28-day treatment cycles. |
Emavusertib will be provided as a tablet dosage form to be taken BID.
Muut nimet:
Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD. |
|
Kokeellinen: Emavusertib (CA-4948) and ibrutinib
In this part of the study (Part C), eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will receive 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD. Treatments will be administered continuously in 28-day treatment cycles. |
Emavusertib will be provided as a tablet dosage form to be taken BID.
Muut nimet:
Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Osa B: kokonaisvastausprosentti (ORR) osallistujilla, joilla on R/R PCNSL
Aikaikkuna: 18 kuukautta
|
18 kuukautta
|
|
|
Osa C: ORR osallistujilla, joilla on R/R PCNSL
Aikaikkuna: 18 kuukautta
|
18 kuukautta
|
|
|
Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)
Aikaikkuna: 12 months
|
The number of participants with a dose-limiting toxicity (DLT) in the first treatment cycle |
12 months
|
|
Part A: Maximum tolerated dose (MTD) of emavusertib as a monotherapy and in combination with ibrutinib measured by dose-limiting toxicities (DLTs)
Aikaikkuna: 12 months
|
MTD determined by the highest dose level studied at which fewer than 2 out of 6 subjects (<33%) experience a dose limiting toxicity. |
12 months
|
|
Part A: Recommended Phase 2 Dose (RP2D) of emavusertib as a monotherapy and in combination with ibrutinib based on overall tolerability data
Aikaikkuna: 12 months
|
RP2D selected based on overall tolerability data from all participants treated at different dose levels and will not exceed the MTD. |
12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Parts A, B and C: Pharmacokinetic (PK) profile of emavusertib and ibrutinib measured by AUC
Aikaikkuna: 24- 66 months
|
Area Under the concentration-time curve (AUC) |
24- 66 months
|
|
Parts A, B and C: Pharmacokinetic (PK) profile of emavusertib and ibrutinib measured by Cmax
Aikaikkuna: 24- 66 months
|
Maximum plasma concentration (Cmax) |
24- 66 months
|
|
Parts A, B and C: Pharmacokinetic (PK) profile of emavusertib and ibrutinib measured by Cmin
Aikaikkuna: 24- 66 months
|
Minimum plasma concentration (Cmin) |
24- 66 months
|
|
Parts A, B and C: Pharmacokinetic (PK) profile of emavusertib and ibrutinib measured by Tmax
Aikaikkuna: 24- 66 months
|
Time to maximum plasma concentration (Tmax) |
24- 66 months
|
|
Parts A, B and C: Pharmacokinetic (PK) profile of emavusertib and ibrutinib measured by plasma terminal half-life
Aikaikkuna: 24- 66 months
|
Plasma terminal elimination half-life (T 1/2) |
24- 66 months
|
|
Part A: To assess efficacy of emavusertib as a monotherapy and in combination with ibrutinib measured by ORR
Aikaikkuna: 24- 36 months
|
Assessed by ORR |
24- 36 months
|
|
Parts A, B and C: To assess efficacy of emavusertib as a monotherapy and in combination with ibrutinib and ibrutinib as monotherapy measured by duration of response (DOR)
Aikaikkuna: 24- 66 months
|
Assessed by DOR |
24- 66 months
|
|
Part A: To assess efficacy of emavusertib as a monotherapy and in combination with ibrutinib measured by disease control rate (DCR)
Aikaikkuna: 24- 36 months
|
Assessed by DCR |
24- 36 months
|
|
Parts A, B and C: To assess efficacy of emavusertib as a monotherapy and in combination with ibrutinib and ibrutinib as monotherapy measured by progression free survival (PFS)
Aikaikkuna: 24- 66 months
|
Assessed by PFS |
24- 66 months
|
|
Parts A, B and C: To assess efficacy of emavusertib as a monotherapy, in combination with ibrutinib and ibrutinib as monotherapy measured by overall survival (OS)
Aikaikkuna: 24 - 66 months
|
Assessed by OS |
24 - 66 months
|
|
Parts B and C: To assess the safety and tolerability of emavusertib as monotherapy, ibrutinib as monotherapy and emavusertib in combination with ibrutinib in participants with R/R PCNSL
Aikaikkuna: up to 66 months
|
Measured by the number of participants with treatment-emergent adverse events (TEAEs) and treatment-related adverse events |
up to 66 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Immuunijärjestelmän sairaudet
- Neoplasmat
- Lymfooma
- NHL
- Lymfooma, non-Hodgkin
- Ibrutinibi
- Lymfoproliferatiiviset häiriöt
- Immunoproliferatiiviset häiriöt
- Lymfaattiset sairaudet
- PCNSL
- Primaarinen keskushermoston lymfooma
- IRAK4
- MYD88
- Uusiutunut/refraktorinen keskushermoston (CNS) lymfooma
- Systeeminen lymfooma samanaikaisesti keskushermoston lymfooman kanssa
- Systeeminen lymfooma, jolla on aiemmin hoidettu keskushermoston lymfooma
- Bruton -tyrosiinikinaasi -inhibiittori (BTKI)
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Neoplasmat sivustoittain
- Sairauden ominaisuudet
- Neoplasmat histologisen tyypin mukaan
- Hematologiset sairaudet
- Patologiset tilat, merkit ja oireet
- Hemic- ja imusuutteet
- Neoplasmat
- Toistuminen
- Hematologiset kasvaimet
- Lymfooma
- Lymfooma, non-Hodgkin
- Lymfoproliferatiiviset häiriöt
- Immuunijärjestelmän sairaudet
- Lymfaattiset sairaudet
- Immunoproliferatiiviset häiriöt
- Ibrutinib
- CA-4948
Muut tutkimustunnusnumerot
- CA-4948-101
- 2024-513312-95-00 (Ctis)
- 2022-000891-20 (EudraCT-numero)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .